Belgium· BE-AMP-SAM286797-00

Neupro 2 mg/24 h

A rotigotine product containing rotigotine, registered in Belgium by UCB Pharma. The same ATC class is registered in 18 of our 19 countries.

ATC N04BC09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedNeupro 2 mg/24 hATCN04BC09REGISTER NO.BE-AMP-SAM286797-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Rotigotine is registered in 18 of 19 countries.

Countries holding a registration under ATC N04BC09 (rotigotine), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose

Rotigotine · ATC N04BC09

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rotigotine costs, country by country.

Normalised to the WHO defined daily dose (6 mg), the median price runs from $0.77 in Czechia to $4.34 in Switzerland — a ×5.6 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Rotigotine · price per daily dose (6 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.34
  • CZ Czechia$0.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Rotigotine
Manufacturer
UCB Pharma
Country
Belgium (BE)
ATC code
N04BC09
ATC class
Rotigotine
Defined daily dose
6 mg, TD
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    2494409
  • be_apb
    2494417

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

58 interactions on record for rotigotine.

Graded by severity as the source publishes them — 58 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rotigotine · interactions on record

58 records

  • 58 moderate

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • ThiethylperazinA04AB03moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rotigotine in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rotigotine products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Kinparlev, Rotigotin Gebro
  • Germany · Rotigotin Luye, Rotigotin Neuraxpharm
  • Denmark · Kinparlev, Rotigotine Medical Valley
  • Spain · Dariante
  • Finland · Kinparlev, Rotigotine Medical Valley
  • France · Rotigotine Arrow
  • Greece · Kinparlev
  • Iceland · Neupro, Rotigotine Medical Valley
  • Italy · Rotigotina Doc
  • Liechtenstein · Neupro
  • Luxembourg · Rotigotin Luye
  • Netherlands · Rotigotine Medical Valley, Rotigotine Xiromed
  • Norway · Kinparlev, Neupro
  • Portugal · Kinparlev, Rotigotina Generis
  • Romania · Kinparlev
  • Sweden · Kinparlev, Rotigotine Medical Valley

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b4542976-d1db-4091-b098-01a37106dc27
GET /v1/drugs/b4542976-d1db-4091-b098-01a37106dc27?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Transdermal patch",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Neupro 2 mg/24 h",
  "name_fr": "Neupro 2 mg/24 h",
  "name_nl": "Neupro 2 mg/24 h",
  "amp_code": "SAM286797-00",
  "strengths": [
    "4.5000",
    "4.5000",
    "4.5000"
  ],
  "pack_count": 10,
  "substances": [
    "Rotigotine"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Rotigotine",
  "authorisation_numbers": [
    "EU/1/05/331/001",
    "EU/1/05/331/002",
    "EU/1/05/331/003",
    "EU/1/05/331/014",
    "EU/1/05/331/015",
    "EU/1/05/331/016",
    "EU/1/05/331/017",
    "EU/1/05/331/018",
    "EU/1/05/331/019",
    "EU/1/05/331/057"
  ]
}

See everything about rotigotine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.